The agreement with PerkinElmer's Wallac Oy subsidiary will bring Mobidiag's real-time PCR-based gastrointestinal tests to a new market.
The deal will help the Finnish diagnostics company expand its offerings of PCR-based gastrointestinal diagnostic tests.
CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.
A study of gut microbes in infants with or without necrotizing enterocolitis points to a uropathogenic Escherichia coli association in infected preterm infants
Under a four-year agreement, Unilabs will offer Mobidiag's Amplidiag products in Sweden and Norway.
Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.
Two new projects announced last week will showcase organ-on-chip technology developed at the Wyss Institute.
The scientists will use gut-on-a-chip technology to develop probiotics that can sense and respond to pathogenic microbes that have made their way into a person's GI system.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
The product introduction comes about two years after the company merged with AmpliDiag and Genewave.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.